RxDoctor Payments Data

Razvan Balotescu, MD

Internal Medicine · Ponte Vedra Beach, FLNPI 1669426094

Payments from drug & device makers

$10,010in general payments, 2019–2025

Across 549 payments — averaging $18.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$978
  • GSK$766
  • AstraZeneca$688
  • Amarin Pharma, Inc.$607
  • Pfizer$566
  • plus $5K from 43 others

What the payments were for

  • Food & beverage$9,995100%
  • Education$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,010 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$153,609
Medicare patients
411
Services billed
2,950

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban47$62,331
OzempicSemaglutide52$54,291
MounjaroTirzepatide38$39,253
JardianceEmpagliflozin28$32,652
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$27,770
TrulicityDulaglutide18$19,136
MyrbetriqMirabegron20$18,770
MovantikNaloxegol Oxalate11$6,169
SynthroidLevothyroxine Sodium50$4,722
Omega-3 Acid Ethyl Esters13$1,835
Rosuvastatin Calcium199$1,669
Valsartan72$1,567
Nebivolol Hcl22$1,486
Gabapentin65$1,439
ValacyclovirValacyclovir Hcl30$1,421

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$566$62,33147 claims
Lilly USA, LLCMounjaro, Trulicity$534$58,38956 claims
Novo NordiskOzempic$1,024$54,29152 claims
Boehringer IngelheimJardiance$365$32,65228 claims
GSKTrelegy Ellipta$766$27,77030 claims
Astellas Pharma US IncMyrbetriq$183$18,77020 claims
AbbVieSynthroid$978$4,72250 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Ponte Vedra Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →